Impact of Pharmacist-led Cognitive Behavioral Intervention on Adherence and Quality of Life of Epileptic Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06034353 |
Recruitment Status :
Active, not recruiting
First Posted : September 13, 2023
Last Update Posted : October 16, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The purpose of this interventional study is to assess the impact of pharmacist-led cognitive behavioral intervention in epileptic patients. The main questions are:
- If pharmacist-led cognitive behavioral therapy can help in improving patient medication adherence?
- How will the cognitive behavioral therapy impact the quality of life of the patients?
Participants of this study will be provided basic or advanced level counselling and educational material as part of their routine pharmacy visit.
Researchers will compare the two groups (Basic and advanced) to see which of the two groups are better in term of medication adherence and quality of life.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Epilepsy | Behavioral: Pharmacist-led Cognitive Behavioral therapy | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 385 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Participant) |
Masking Description: | Participants will be entertained as part of their regular appointment for prescription filling without any information of which group they are assigned in. |
Primary Purpose: | Supportive Care |
Official Title: | Impact of Pharmacist-led Cognitive Behavioral Intervention on Adherence and Quality of Life of Epileptic Patients |
Actual Study Start Date : | September 22, 2023 |
Estimated Primary Completion Date : | January 30, 2024 |
Estimated Study Completion Date : | March 15, 2024 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Basic group
Lifestyle Modifications: General education about healthy life style and diet. Education : general awareness about disease and medication Pill Planner: Pill planner will be provided to keep them adherent to their medication Counselling: Counsel the patients about there medication dosage, frequency and appropriate time.
|
Behavioral: Pharmacist-led Cognitive Behavioral therapy
Pharmacist-led Cognitive Behavioral therapy is patient centered approach that focus both physical and emotional aspect of health is provided. It is focused to identify negative and change negative thought pattern and behavior to improve mental and physical well being.Incorporation education about healthy meal choices, relaxation techniques, self management strategies,to improve education about potential adverse effect, how to recognize and on followup calls how to adjust medication doses along with this is provided. |
Experimental: Advanced
Lifestyle Modifications: Specific education on keto-diet, yoga and meditation Education : Specific disease education targeting medication adverse drug reaction (ADR), seizure chart management Pill Planner: Pill planner will also be provided to this group Counselling: Cognitive Behavioral therapy will be provided
|
Behavioral: Pharmacist-led Cognitive Behavioral therapy
Pharmacist-led Cognitive Behavioral therapy is patient centered approach that focus both physical and emotional aspect of health is provided. It is focused to identify negative and change negative thought pattern and behavior to improve mental and physical well being.Incorporation education about healthy meal choices, relaxation techniques, self management strategies,to improve education about potential adverse effect, how to recognize and on followup calls how to adjust medication doses along with this is provided. |
- Medication adherence [ Time Frame: 3 months ]
Adherence will be assessed using (Medication Adherence Reporting Scale) MARS-10.
This scale describes three-dimension, Medication adherence behavior (1-4), attitude towards taking medication (5-8), negative side effects and attitudes to psychotropic medication (9-10). Each question has Yes and No response, a response consistent with adherence is coded as 1 and with non-adherence coded as 0. Higher the score higher will be the adherence. Adherence <6 is poor adherence, and >8 is high adherence.
- Quality of life of Epileptic patients [ Time Frame: 3 months ]Patient's quality of life will be assessed using Quality of life for epilepsy scale(QOLIE-31). QOLIE-31(Quality of life in epilepsy) used for quality-of-life assessment which assess the patient's life's quality level along using anti-epileptic drug (AED) therapy through close ended questions with a score. The score can range from 0-100, with 100 representing the best quality of life.
- Incidence of Drug-Drug Interactions [ Time Frame: 3 months ]Drug interactions among epileptic and non-epileptic drug will be assessed using standard website (update-Lexicomp) It is used to access the reduction in no. of drug drug interaction after pharmacist intervation in both basic and advance groups.
- Incidence of Adverse reactions [ Time Frame: 3 months ]
Adverse reactions of all anti-epileptic drug will be noted while assessing a patient.
It is used to access the reduction in frequency of Adverse drug reaction after pharmacist intervation in both basic and advance groups.
- Rate of seizures per week [ Time Frame: 3 months ]While assessing patient no. of seizures per week is asked and noted by the pharmacist. After intervening both basic and advance group impact of intervation is accessed for no. of seizures in the groups.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 15 Years to 70 Years (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with confirmed diagnosis.
- Patients treated for epilepsy with at least one anti epileptic drug, subjects willing to participate in the study with or without other severe co-morbidities were included in the study.
Exclusion Criteria:
- Pregnant female patients.
- Patients who provide incomplete information
- Patients with any terminal disease e.g., end stage renal disease
- Patients not willing to participate were excluded from the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06034353
Pakistan | |
Shifa International Hospital | |
Islamabad, Pakistan |
Study Director: | Matti Ullah, PhD | Hamdard University Islamabad Campus | |
Principal Investigator: | Iqra Farooq, MPhil | Shifa International Hospital | |
Study Chair: | Muhammad Shafiq, BS. (Hons.) | Subhan Medical Trust | |
Study Chair: | Emmama Jamil, MPhil | Hamdard University Islamabad Campus |
Responsible Party: | Matti Ullah, Assistant Professor, Hamdard University |
ClinicalTrials.gov Identifier: | NCT06034353 |
Other Study ID Numbers: |
NA0823 |
First Posted: | September 13, 2023 Key Record Dates |
Last Update Posted: | October 16, 2023 |
Last Verified: | October 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Plan Description: | Sharing patient data will depend on the patient's consent. If the patient doesn't allow to share data with others, we will not be able to share individual data. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Cognitive behavioral therapy Pharmacist Medication Adherence Quality of life |